Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 21.51 USD -2.09% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Arrowhead Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

ARWR Price Targets Summary
Arrowhead Pharmaceuticals Inc

Wall Street analysts forecast ARWR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARWR is 48.23 USD with a low forecast of 20.2 USD and a high forecast of 74.55 USD.

Lowest
Price Target
20.2 USD
6% Downside
Average
Price Target
48.23 USD
124% Upside
Highest
Price Target
74.55 USD
247% Upside

ARWR Last Price Targets
Arrowhead Pharmaceuticals Inc

The latest public price target was made on Sep 3, 2024 by David Lebowitz from Citigroup , who expects ARWR stock to rise by 26% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Lebowitz
Citigroup
27 USD
Upside 26%
2 months ago
Sep 3, 2024
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
StreetInsider
Patrick Trucchio
H.C. Wainwright
60 USD
Upside 179%
4 months ago
Jul 5, 2024
Arrowhead Pharma (ARWR) PT Lowered to $60 at H.C. Wainwright
StreetInsider
Andrea Tan
Goldman Sachs
31 USD
Upside 44%
5 months ago
Jun 5, 2024
Goldman Sachs Starts Arrowhead Pharma (ARWR) at Neutral
StreetInsider
Luca Issi
RBC Capital
50 USD
Upside 132%
5 months ago
May 30, 2024
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
StreetInsider
Unknown Analyst
RBC Capital
77 USD
Upside 258%
1 year ago
Feb 7, 2023
RBC Capital Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $77
Benzinga
Unknown Analyst
Piper Sandler
52 USD
Upside 142%
1 year ago
Feb 7, 2023
Piper Sandler Maintains Overweight on Arrowhead Pharma, Lowers Price Target to $52
Benzinga
Show More Price Targets
Show Less Price Targets
David Lebowitz
Citigroup
Price Target 27 USD
Upside/Downside 26%
View Source
Patrick Trucchio
H.C. Wainwright
Price Target 60 USD
Upside/Downside 179%
View Source
Andrea Tan
Goldman Sachs
Price Target 31 USD
Upside/Downside 44%
View Source
Luca Issi
RBC Capital
Price Target 50 USD
Upside/Downside 132%
View Source
Unknown Analyst
RBC Capital
Price Target 77 USD
Upside/Downside 258%
View Source
Unknown Analyst
Piper Sandler
Price Target 52 USD
Upside/Downside 142%
View Source
Show More Price Targets
Show Less Price Targets
Arrowhead Pharmaceuticals Inc Competitors:
Price Targets
LTRN
Lantern Pharma Inc.
527% Upside
CRVO
Diffusion Pharmaceuticals Inc
397% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
30% Upside
6160
Beigene Ltd
16% Upside
SGMO
Sangamo Therapeutics Inc
43% Upside
SIGHT
Gensight Biologics SA
27% Upside
AVTE
Aerovate Therapeutics Inc
11% Downside

Revenue
Forecast

Revenue Estimate
Arrowhead Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Arrowhead Pharmaceuticals Inc's revenue is 123%. The projected CAGR for the next 4 years is 18%.

123%
Past Growth
18%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Arrowhead Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Arrowhead Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ARWR's stock price target?
Price Target
48.23 USD

According to Wall Street analysts, the average 1-year price target for ARWR is 48.23 USD with a low forecast of 20.2 USD and a high forecast of 74.55 USD.

What is Arrowhead Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for Arrowhead Pharmaceuticals Inc's revenue is 123%. The projected CAGR for the next 4 years is 18%.

Back to Top